Peregrine Pharmaceuticals to Participate in Two Upcoming Life Science Investor Conferences
November 23 2015 - 8:05AM
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a
biopharmaceutical company focused on developing therapeutics to
stimulate the body's immune system to fight cancer, today announced
that the company will participate in two upcoming life science
investor conferences being held in New York during the month of
December. Steven W. King, president and chief executive
officer, will participate in a panel discussion focused on cancer
immunotherapy at Piper Jaffray’s 27th Annual Healthcare
Conference. Additionally, the company will be one of only 16
life science companies attending Roth Capital Partners’
Immuno-Oncology Corporate Access Day.
|
|
|
Details of Peregrine’s Piper Jaffray
conference participation are as follows: |
|
|
|
Conference: |
|
Piper Jaffray 27th Annual Healthcare
Conference |
|
|
|
Date: |
|
December 1-2, 2015 |
|
|
|
Panel Title: |
|
Under-Discovered OncoInnovators |
|
|
|
Panel Time: |
|
December 1, 2015, 3:00 – 4:00 p.m. (Eastern) |
|
|
|
Location: |
|
Lotte New York Palace Hotel |
|
|
|
|
|
|
Details of Peregrine’s Roth Capital
Partners conference participation are as follows: |
|
|
|
Conference: |
|
Roth Capital Partners Immuno-Oncology Corporate
Access Day |
|
|
|
Date: |
|
December 16, 2015 |
|
|
|
Location: |
|
Park Hyatt New York Hotel |
|
|
|
About Bavituximab: A Targeted
Investigational Immunotherapy
Bavituximab is an investigational chimeric
monoclonal antibody that targets phosphatidylserine (PS). Signals
from PS inhibit the ability of immune cells to recognize and fight
tumors. Bavituximab, the lead compound in Peregrine's
immuno-oncology development program, blocks PS to remove this
immunosuppressive signal and sends an alternate immune activating
signal. PS targeting antibodies have been shown to shift the
functions of immune cells in tumors, resulting in robust anti-tumor
immune responses.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company
with a pipeline of novel drug candidates in clinical trials focused
on the treatment of cancer. The company's lead immunotherapy
candidate, bavituximab, is in Phase III development for the
treatment of previously treated non-small cell lung cancer (the
"SUNRISE trial") along with several investigator-sponsored trials
evaluating other treatment combinations and additional oncology
indications. Peregrine also has in-house cGMP manufacturing
capabilities through its wholly-owned subsidiary Avid Bioservices,
Inc. (www.avidbio.com), which provides development and
biomanufacturing services for both Peregrine and third-party
customers. For more information, please visit
www.peregrineinc.com.
Contacts:
Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024